GLPG Galapagos NV - American Deposit

76.36
-2.64  -3%
Previous Close 79.00
Open 78.27
Price To book 4.36
Market Cap 3.53B
Shares 46,256,000
Volume 196,881
Short Ratio 2.68
Av. Daily Volume 216,494

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 recruitment to be completed by end of 2017.
GLPG1972
Osteoarthritis
Phase 2 trial announced April 25, 2017.
Filgotinib
Cutaneous lupus erythematosus (CLE)
Phase 3 initiated August 2016
Filgotinib - FINCH 4
Rheumatoid arthritis (RA)
Phase 3 initiated August 2016.
Filgotinib - FINCH 3
Rheumatoid arthritis (RA)
Phase 3 initiated August 2016.
Filgotinib - FINCH 2
Rheumatoid arthritis (RA)
Phase 2 initiation announced April 4, 2017.
Filgotinib - EQUATOR
Psoriatic arthritis
Phase 2 initiation announced April 4, 2017.
Filgotinib - TORTUGA
Ankylosing spondylitis
Phase 2 initiation announced April 4, 2017.
Filgotinib
Sjögren’s syndrome
Announced February 1, 2017 that Phase 2a dosing has commenced. Top-line data due 4Q 2017.
GLPG2222 - ALBATROSS
Cystic fibrosis (CF)
Phase 2 top-line data released December 20, 2016.
GLPG1837
Cystic Fibrosis
Phase 2a top-line data due 3Q 2017.
GLPG1690 - FLORA
Idiopathic pulmonary fibrosis
Phase 2/3 trial initiation announced December 8, 2016.
Filgotinib - SELECTION
Ulcerative colitis
Phase 3 initiated November 2016.
Filgotinib - DIVERSITY
Crohn’s disease
Phase 3 initiated August 2016
Filgotinib - FINCH 1
Rheumatoid arthritis (RA)

Latest News

  1. Galapagos increases share capital through warrant exercises
  2. Galapagos' R&D Update 2017: rapidly advancing our product candidates
  3. Galapagos creates new warrant plan
  4. Seven abstracts on filgotinib accepted by EULAR 2017
  5. 3 Top Biotech Stocks For May
  6. Galapagos presents three posters on filgotinib in Crohn's disease at DDW® 2017
  7. Galapagos NV :GLPG-US: Earnings Analysis: Q1, 2017 By the Numbers : May 4, 2017
  8. Galapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis at OARSI
  9. ETFs with exposure to Galapagos NV : April 28, 2017
  10. Galapagos reports first quarter 2017 results
  11. Galapagos announces new Phase 2 Proof-of-Concept study with filgotinib in cutaneous lupus erythematosus
  12. Galapagos announces closing of public offering of American Depositary Shares for gross proceeds of €363.9 million
  13. Galapagos raises $338 million gross proceeds in a U.S. public offering
  14. Galapagos announces launch of proposed public offering
  15. Galapagos doses first psoriatic arthritis patient with filgotinib
  16. Galapagos Initiates 3 Phase II Studies for Filgotinib
  17. Galapagos announces three new Phase 2 Proof-of-Concept studies with filgotinib
  18. The Zacks Analyst Blog Highlights: Milacron Holdings, Galapagos NV and Raymond James Financial